FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2104301864> ?p ?o ?g. }

• W2104301864 endingPage "54" @default.
• W2104301864 startingPage "49" @default.
• W2104301864 abstract "Background In the phase III CLARITY study, treatment with cladribine tablets at cumulative doses of 3.5 or 5.25 mg/kg over 96 weeks led to significant reductions in annualized relapse rates (ARR) versus placebo in patients with relapsing–remitting multiple sclerosis. Further post hoc analyses of CLARITY study data were conducted to determine the efficacy of cladribine tablets across patient subgroups stratified by baseline characteristics. Methods Relapse rates over the 96-week CLARITY study were analyzed in cohorts stratified by demographics; disease duration; treatment history and disease activity at baseline. Results In the intent-to-treat population (n=437, 433 and 456 in the placebo, cladribine 3.5 and 5.25 mg/kg groups, respectively), treatment with cladribine tablets 3.5 and 5.25 mg/kg led to consistent improvements in ARR versus placebo in patients stratified by gender; age (≤40/>40 years); disease duration (<3/3–10/>10 years); prior disease-modifying drug treatment (treated/naïve); relapses in the prior year (≤1/2/≥3); Expanded Disability Status Scale score (<3.5/≥3.5); T1 gadolinium-enhancing lesions (presence, absence); and T2 lesion volume (≤median/>median) at baseline (all P≤0.05 for reduction in the relative risk of relapse [cladribine tablets versus placebo]). Significant effects were also observed in patients who had only one relapse in the year prior to study entry (n=306, 303 and 323 in the placebo, cladribine 3.5 and 5.25 mg/kg groups, respectively) and who were further stratified according to other measures of disease activity at baseline. Conclusions Treatment with cladribine tablets provides consistent reductions in ARR compared with placebo across the spectrum of baseline demographics and disease characteristics represented in the CLARITY study." @default.
• W2104301864 created "2016-06-24" @default.
• W2104301864 creator A5015754502 @default.
• W2104301864 creator A5018024307 @default.
• W2104301864 creator A5025462803 @default.
• W2104301864 creator A5043178404 @default.
• W2104301864 creator A5049696879 @default.
• W2104301864 creator A5066796645 @default.
• W2104301864 creator A5069481185 @default.
• W2104301864 creator A5076375869 @default.
• W2104301864 creator A5089091782 @default.
• W2104301864 date "2012-01-01" @default.
• W2104301864 modified "2023-10-01" @default.
• W2104301864 title "Cladribine tablets for relapsing–remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study" @default.
• W2104301864 cites W1966298565 @default.
• W2104301864 cites W1968656445 @default.
• W2104301864 cites W1978971614 @default.
• W2104301864 cites W1980782289 @default.
• W2104301864 cites W1999175233 @default.
• W2104301864 cites W2004076487 @default.
• W2104301864 cites W2038860593 @default.
• W2104301864 cites W2105490558 @default.
• W2104301864 cites W2107424415 @default.
• W2104301864 cites W2112165124 @default.
• W2104301864 cites W2122894564 @default.
• W2104301864 cites W2127001605 @default.
• W2104301864 cites W2135900660 @default.
• W2104301864 cites W2139204856 @default.
• W2104301864 cites W2147062889 @default.
• W2104301864 cites W2148186809 @default.
• W2104301864 cites W4211254511 @default.
• W2104301864 doi "https://doi.org/10.1016/j.msard.2011.08.006" @default.
• W2104301864 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25876451" @default.
• W2104301864 hasPublicationYear "2012" @default.
• W2104301864 type Work @default.
• W2104301864 sameAs 2104301864 @default.
• W2104301864 citedByCount "28" @default.
• W2104301864 countsByYear W21043018642013 @default.
• W2104301864 countsByYear W21043018642017 @default.
• W2104301864 countsByYear W21043018642018 @default.
• W2104301864 countsByYear W21043018642019 @default.
• W2104301864 countsByYear W21043018642020 @default.
• W2104301864 countsByYear W21043018642021 @default.
• W2104301864 countsByYear W21043018642022 @default.
• W2104301864 countsByYear W21043018642023 @default.
• W2104301864 crossrefType "journal-article" @default.
• W2104301864 hasAuthorship W2104301864A5015754502 @default.
• W2104301864 hasAuthorship W2104301864A5018024307 @default.
• W2104301864 hasAuthorship W2104301864A5025462803 @default.
• W2104301864 hasAuthorship W2104301864A5043178404 @default.
• W2104301864 hasAuthorship W2104301864A5049696879 @default.
• W2104301864 hasAuthorship W2104301864A5066796645 @default.
• W2104301864 hasAuthorship W2104301864A5069481185 @default.
• W2104301864 hasAuthorship W2104301864A5076375869 @default.
• W2104301864 hasAuthorship W2104301864A5089091782 @default.
• W2104301864 hasConcept C126322002 @default.
• W2104301864 hasConcept C142724271 @default.
• W2104301864 hasConcept C203014093 @default.
• W2104301864 hasConcept C204787440 @default.
• W2104301864 hasConcept C27081682 @default.
• W2104301864 hasConcept C2779200787 @default.
• W2104301864 hasConcept C2780640218 @default.
• W2104301864 hasConcept C2780892749 @default.
• W2104301864 hasConcept C2908647359 @default.
• W2104301864 hasConcept C67761136 @default.
• W2104301864 hasConcept C71924100 @default.
• W2104301864 hasConcept C90924648 @default.
• W2104301864 hasConcept C99454951 @default.
• W2104301864 hasConceptScore W2104301864C126322002 @default.
• W2104301864 hasConceptScore W2104301864C142724271 @default.
• W2104301864 hasConceptScore W2104301864C203014093 @default.
• W2104301864 hasConceptScore W2104301864C204787440 @default.
• W2104301864 hasConceptScore W2104301864C27081682 @default.
• W2104301864 hasConceptScore W2104301864C2779200787 @default.
• W2104301864 hasConceptScore W2104301864C2780640218 @default.
• W2104301864 hasConceptScore W2104301864C2780892749 @default.
• W2104301864 hasConceptScore W2104301864C2908647359 @default.
• W2104301864 hasConceptScore W2104301864C67761136 @default.
• W2104301864 hasConceptScore W2104301864C71924100 @default.
• W2104301864 hasConceptScore W2104301864C90924648 @default.
• W2104301864 hasConceptScore W2104301864C99454951 @default.
• W2104301864 hasIssue "1" @default.
• W2104301864 hasLocation W21043018641 @default.
• W2104301864 hasLocation W21043018642 @default.
• W2104301864 hasOpenAccess W2104301864 @default.
• W2104301864 hasPrimaryLocation W21043018641 @default.
• W2104301864 hasRelatedWork W160847151 @default.
• W2104301864 hasRelatedWork W2761038804 @default.
• W2104301864 hasRelatedWork W2808865397 @default.
• W2104301864 hasRelatedWork W3005612528 @default.
• W2104301864 hasRelatedWork W3011181018 @default.
• W2104301864 hasRelatedWork W3188666067 @default.
• W2104301864 hasRelatedWork W3205870417 @default.
• W2104301864 hasRelatedWork W4362469295 @default.
• W2104301864 hasRelatedWork W4367303252 @default.
• W2104301864 hasRelatedWork W4386034949 @default.
• W2104301864 hasVolume "1" @default.
• W2104301864 isParatext "false" @default.

• next